A practical reference on reversed-phase HPLC: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-16 and is reviewed periodically as new material appears.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the dominant approach for peptide purity assessment, usually paired with mass spectrometry to confirm molecular mass and sequence. Peptide mapping by enzymatic digestion and tandem mass spectrometry locates modifications such as deamidation and oxidation. Quantitation in plasma matrices can be performed by LC-MS/MS after solid-phase extraction. Method validation follows general guidance on accuracy, precision, linearity, and limits of detection. Comparability of results between laboratories, when no shared reference standard is available, remains an open question.
Stability studies focus on deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation into higher-order species. The fatty acid side chain adds susceptibility to oxidative change and can promote self-association at high concentration. Lyophilised material is comparatively robust when kept cold and dry, while aqueous solutions require refrigeration and protection from light. Forced degradation experiments under heat, acid, base, and peroxide conditions establish the specificity of each analytical method. Which degradation route dominates under real storage conditions depends on the formulation and stays formulation-specific.
Handling guidance for research quantities calls for single-use aliquots, an inert atmosphere where practical, and avoidance of repeated freeze-thaw cycles that accelerate aggregation. Certificates of analysis typically report purity by peak area, water content, counter-ion identity, and residual solvent levels. In the scientific literature the compound is usually described by its full amino acid sequence, its registry number, or its structural class rather than by any proprietary label. Reporting standards vary between journals, and reviewers increasingly request raw chromatograms alongside tabulated purity figures. Whether current purity thresholds are adequate for every experimental context is debated.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | Not a small molecule |
| Backbone substitutions | Non-natural residue at position 8, arginine at position 34 | Slows enzymatic cleavage |
| Side chain | C18 fatty diacid with PEG linker | Enables albumin binding |
| Approximate molecular mass | 4114 Da | Varies slightly with salt form |
| Reported half-life | About one week | Longer than native GLP-1 by orders of magnitude |
Quality control relies on pharmacopoeial monographs where they exist, combined with in-house specifications for identity, purity, water content, and counter-ion composition. Reference standards allow calibration across laboratories, although certified materials for every analogue are not universally obtainable. Batch records, chromatograms, and mass spectra form the documentation trail. Regulatory classification varies by jurisdiction and intended use, and research-grade material differs from pharmaceutical-grade material in testing scope. Analytical uncertainty is often expressed as relative standard deviation across replicate injections.
Lyophilised semaglutide is generally held at -20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept at 2-8 °C and used within a defined window because degradation accumulates over time. Repeated freeze-thaw cycles are discouraged, since each cycle can promote aggregation and reduce monomeric content. Room-temperature stability of the solid has been examined in some studies but remains incompletely characterised for long durations, so cold storage is the conservative default for research material.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Storage conditions for semaglutide depend heavily on the presentation. Lyophilized research powder is generally kept at two to eight degrees Celsius in a sealed container, protected from light and moisture. Manufacturer labeling for finished injectable products specifies refrigeration before first use, with defined in-use periods at room temperature afterward. The oral tablet form is stored at controlled room temperature and is more tolerant of short excursions. Temperature excursions should be documented rather than inferred.
Peptide degradation follows several routes. Hydrolysis cleaves the backbone at susceptible residues, oxidation targets methionine and tryptophan side chains, and aggregation produces higher-molecular-weight species that are difficult to reverse. Light exposure accelerates oxidation, which is why amber glass or opaque secondary packaging is common. Repeated freeze-thaw cycles promote aggregation and are best avoided. Stability-indicating methods detect these changes before they become visible.
Quality control for research material typically involves reversed-phase HPLC for purity and identity, mass spectrometry for molecular weight confirmation, and Karl Fischer titration for residual water content. Peptide content is often reported as the mass of actual peptide rather than total powder mass, since counterions and water contribute to the latter. A certificate of analysis should list the method used for each specification. Limits and acceptance criteria vary by supplier and by intended application.
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
Quantification and purity assessment rely on separation methods coupled to optical or mass detection. Reversed-phase high-performance liquid chromatography resolves the intact peptide from related impurities and is the standard assay technique. Size-exclusion chromatography measures aggregates, while ion-exchange chromatography separates charge variants produced by deamidation. Mass spectrometry confirms identity and detects mass shifts of a few daltons. In biological matrices, liquid chromatography with tandem mass spectrometry is often used because immunoassays can cross-react with endogenous GLP-1 or with circulating fragments.
The Sumerians are said to have cultivated and harvested the opium poppy (Papaver somniferum) in lower Mesopotamia as early as 3400 BC, though this has been disputed. The most ancient testimony concerning the opium poppy found to date was inscribed in cuneiform script on a small white clay tablet at the end of the third millennium BC. This tablet was discovered in 1954 during excavations at Nippur, and is currently kept at the University of Pennsylvania Museum of Archaeology and Anthropology. Deciphered by Samuel Noah Kramer and Martin Leve, it is considered to be the most ancient pharmacopoeia in existence. Some Sumerian tablets of this era have an ideogram inscribed upon them, "hul gil", which translates to "plant of joy", believed by some authors to refer to opium. The term gil is still used for opium in certain parts of the world. The Sumerian goddess Nidaba is often depicted with poppies growing out of her shoulders. About 2225 BC, the Sumerian territory became a part of the Babylonian empire. Knowledge and use of the opium poppy and its euphoric effects thus passed to the Babylonians, who expanded their empire eastwards to Persia and westwards to Egypt, thereby extending its range to these civilizations. British archaeologist and cuneiformist Reginald Campbell Thompson writes that opium was known to the Assyrians in the 7th century BC. The term "Arat Pa Pa" occurs in the Assyrian Herbal, a collection of inscribed Assyrian tablets dated to c. 650 BC.
Journal of Military History. 65 (3): 617–640. doi:10.2307/2677528. JSTOR 2677528. S2CID 159945703. McEvedy, Colin; Jones, Richard (1978). Atlas of World Population History. Facts on File. ISBN 978-0-87196-402-1. McLynn, Frank (1998). Napoleon: A Biography. Pimlico. ISBN 978-0-7126-6247-5. Munch-Petersen, Thomas (2007). Defying Napoleon: How Britain Bombarded Copenhagen and Seized the Danish Fleet in 1807. Sutton. ISBN 978-0-7509-4280-5. Palmer, Robert Roswell (1941). Twelve who Ruled: The Committee of Public Safety, During the Terror. Princeton University Press. Palmer, Alan (1974). Alexander I: Tsar of War and Peace. Weidenfeld & Nicolson. ISBN 978-0-297-76700-8. Palmer, R. R.; Colton, Joel; Kramer, Lloyd (2013). A History of the Modern World: 11th Edition. McGraw-Hill Higher Education. ISBN 978-0-07-759962-1. Payne, Stanley G. (1973). A History of Spain and Portugal: Eighteenth Century to Franco. Vol. 2. Madison: University of Wisconsin Press. ISBN 978-0299062705. Retrieved 2 May 2021. Philo, Tom (2010), Military and Civilian War Related Deaths Through the Ages, archived from the original on 20 April 2010 Rapport, Mike (2013). The Napoleonic Wars: A Very Short Introduction. OUP Oxford. ISBN 978-0-19-164251-7. Riehn, Richard K. (1990). 1812: Napoleon's Russian Campaign. McGraw-Hill. ISBN 978-0-07-052731-7. Riehn, Richard K. (1991), 1812: Napoleon's Russian Campaign (Paperback ed.), New York: Wiley, ISBN 978-0-471-54302-2 Riley, J. P. (2013). Napoleon and the World War of 1813: Lessons in Coalition Warfighting. Routledge. ISBN 978-1-136-32135-1. Roberts, Andrew (2014).
=== MeSH D12.644.360 – intracellular signaling peptides and proteins === MeSH D12.644.360.011 – activating transcription factor 6 MeSH D12.644.360.024 – adaptor proteins, signal transducing MeSH D12.644.360.024.264 – caveolin 1 MeSH D12.644.360.024.272 – caveolin 2 MeSH D12.644.360.024.280 – cortactin MeSH D12.644.360.024.295 – crk-associated substrate protein MeSH D12.644.360.024.297 – grb2 adaptor protein MeSH D12.644.360.024.298 – grb7 adaptor protein MeSH D12.644.360.024.300 – grb10 adaptor protein MeSH D12.644.360.024.301 – interferon-stimulated gene factor 3 MeSH D12.644.360.024.301.500 – interferon-stimulated gene factor 3, alpha subunit MeSH D12.644.360.024.301.500.500 – stat1 transcription factor MeSH D12.644.360.024.301.500.750 – stat2 transcription factor MeSH D12.644.360.024.301.750 – interferon-stimulated gene factor 3, gamma subunit MeSH D12.644.360.024.303 – interferon regulatory factors MeSH D12.644.360.024.303.124 – interferon regulatory factor-1 MeSH D12.644.360.024.303.249 – interferon regulatory factor-2 MeSH D12.644.360.024.303.374 – interferon regulatory factor-3 MeSH D12.644.360.024.303.437 – interferon regulatory factor-7 MeSH D12.644.360.024.303.500 – interferon-stimulated gene factor 3, gamma subunit MeSH D12.644.360.024.305 – pii nitrogen regulatory proteins MeSH D12.644.360.024.307 – paxillin MeSH D12.644.360.024.311 – protein inhibitors of activated STAT MeSH D12.644.360.024.313 – 14-3-3 proteins MeSH D12.644.360.024.318 – proto-oncogene proteins c-crk MeSH D12.644.360.024.326 – proto-oncogene proteins c-vav MeSH D12.644.360.024.334 – smad proteins MeSH D12.644.360.024.334.200 – smad proteins, inhibitory MeSH D12.644.360.024.334.200.600 – smad6 protein MeSH D12.644.360.024.334.200.700 – smad7 protein MeSH D12.644.360.024.334.500 – smad proteins, receptor-regulated MeSH D12.644.360.024.334.500.100 – smad1 protein MeSH D12.644.360.024.334.500.200 – smad2 protein MeSH D12.644.360.024.334.500.300 – smad3 protein MeSH D12.644.360.024.334.500.500 – smad5 protein MeSH D12.644.360.024.334.500.800 – smad8 protein MeSH D12.644.360.024.334.750 – smad4 protein MeSH D12.644.360.024.342 – stat transcription factors MeSH D12.644.360.024.342.100 – stat1 transcription factor MeSH D12.644.360.024.342.200 – stat2 transcription factor MeSH D12.644.360.024.342.300 – stat3 transcription factor MeSH D12.644.360.024.342.400 – stat4 transcription factor MeSH D12.644.360.024.342.500 – stat5 transcription factor MeSH D12.644.360.024.342.600 – stat6 transcription factor MeSH D12.644.360.024.374 – suppressor of cytokine signaling proteins MeSH D12.644.360.024.500 – tumor necrosis factor receptor-associated peptides and proteins MeSH D12.644.360.024.500.500 – tnf receptor-associated factor 1 MeSH D12.644.360.024.500.750 – tnf receptor-associated factor 2 MeSH D12.644.360.024.500.875 – tnf receptor-associated factor 3 MeSH D12.644.360.024.500.937 – tnf receptor-associated factor 5 MeSH D12.644.360.024.500.968 – tnf receptor-associated factor 6 MeSH D12.644.360.050 – adenylate cyclase MeSH D12.644.360.075 – apoptosis regulatory proteins MeSH D12.644.360.075.311 – apoptosis inducing factor MeSH D12.644.360.075.405 – caspases MeSH D12.644.360.075.405.200 – caspase 1 MeSH D12.644.360.075.437 – inhibitor of apoptosis proteins MeSH D12.644.360.075.437.500 – neuronal apoptosis-inhibitory protein MeSH D12.644.360.075.437.750 – x-linked inhibitor of apoptosis protein MeSH D12.644.360.075.718 – proto-oncogene proteins c-bcl-2 MeSH D12.644.360.075.718.100 – bcl-associated death protein MeSH D12.644.360.075.718.400 – bcl-2-associated x protein MeSH D12.644.360.075.718.750 – bcl-2 homologous antagonist-killer protein MeSH D12.644.360.075.718.937 – bcl-x protein MeSH D12.644.360.075.718.968 – bh3 interacting domain death agonist protein MeSH D12.644.360.100 – ca(2+)-calmodulin dependent protein kinase MeSH D12.644.360.100.500 – myosin-light-chain kinase MeSH D12.644.360.150 – casein kinases MeSH D12.644.360.150.300 – casein kinase i MeSH D12.644.360.150.300.100 – casein kinase ialpha MeSH D12.644.360.150.300.200 – casein kinase idelta MeSH D12.644.360.150.300.300 – casein kinase iepsilon MeSH D12.644.360.150.600 – casein kinase ii MeSH D12.644.360.200 – cyclic nucleotide-regulated protein kinases MeSH D12.644.360.200.125 – cyclic amp-dependent protein kinases MeSH D12.644.360.200.125.500 – beta-adrenergic receptor kinase MeSH D12.644.360.200.150 – cyclic gmp-dependent protein kinases MeSH D12.644.360.200.575 – protamine kinase MeSH D12.644.360.250 – cyclin-dependent kinases MeSH D12.644.360.250.067 – cdc2-cdc28 kinases MeSH D12.644.360.250.067.249 – cdc2 protein kinase MeSH D12.644.360.250.067.500 – cdc28 protein kinase, s cerevisiae MeSH D12.644.360.250.067.875 – cyclin-dependent kinase 5 MeSH D12.644.360.250.067.900 – cyclin-dependent kinase 9 MeSH D12.644.360.250.323 – cyclin-dependent kinase 2 MeSH D12.644.360.250.451 – cyclin-dependent kinase 4 MeSH D12.644.360.250.515 – cyclin-dependent kinase 6 MeSH D12.644.360.250.580 – maturation-promoting factor MeSH D12.644.360.250.580.500 – cdc2 protein kinase MeSH D12.644.360.275 – eif-2 kinase MeSH D12.644.360.287 – focal adhesion protein-tyrosine kinases MeSH D12.644.360.300 – glycogen synthase kinases MeSH D12.644.360.300.500 – glycogen synthase kinase 3 MeSH D12.644.360.325 – gtp-binding protein regulators MeSH D12.644.360.325.150 – gtpase-activating proteins MeSH D12.644.360.325.150.100 – chimerin proteins MeSH D12.644.360.325.150.100.200 – chimerin 1 MeSH D12.644.360.325.150.300 – eukaryotic initiation factor-5 MeSH D12.644.360.325.150.500 – ras gtpase-activating proteins MeSH D12.644.360.325.150.500.460 – neurofibromin 1 MeSH D12.644.360.325.150.500.500 – p120 gtpase activating protein MeSH D12.644.360.325.150.750 – rgs proteins MeSH D12.644.360.325.225 – guanine nucleotide dissociation inhibitors MeSH D12.644.360.325.300 – guanine nucleotide exchange factors MeSH D12.644.360.325.300.200 – eukaryotic initiation factor-2b MeSH D12.644.360.325.300.300 – guanine nucleotide-releasing factor 2 MeSH D12.644.360.325.300.450 – proto-oncogene proteins c-vav MeSH D12.644.360.325.300.600 – ral guanine nucleotide exchange factor MeSH D12.644.360.325.300.700 – ras guanine nucleotide exchange factors MeSH D12.644.360.325.300.700.500 – ras-grf1 MeSH D12.644.360.325.300.700.700 – son of sevenless proteins MeSH D12.644.360.325.300.700.700.600 – son of sevenless protein, drosophila MeSH D12.644.360.325.300.700.700.630 – sos1 protein MeSH D12.644.360.350 – guanylate cyclase MeSH D12.644.360.375 – heterotrimeric gtp-binding proteins MeSH D12.644.360.375.100 – gtp-binding protein alpha subunits MeSH D12.644.360.375.100.100 – gtp-binding protein alpha subunits, g12-g13 MeSH D12.644.360.375.100.200 – gtp-binding protein alpha subunits, gi-go MeSH D12.644.360.375.100.200.500 – gtp-binding protein alpha subunit, gi2 MeSH D12.644.360.375.100.300 – gtp-binding protein alpha subunits, gq-g11 MeSH D12.644.360.375.100.400 – gtp-binding protein alpha subunits, gs MeSH D12.644.360.375.520 – gtp-binding protein beta subunits MeSH D12.644.360.375.730 – gtp-binding protein gamma subunits MeSH D12.644.360.375.940 – transducin MeSH D12.644.360.376 – i-kappa b kinase MeSH D12.644.360.378 – i-kappa b proteins MeSH D12.644.360.381 – intracellular calcium-sensing proteins MeSH D12.644.360.381.249 – calmodulin MeSH D12.644.360.381.311 – calnexin MeSH D12.644.360.381.374 – calreticulin MeSH D12.644.360.381.437 – gelsolin MeSH D12.644.360.381.500 – neuronal calcium-sensor proteins MeSH D12.644.360.381.500.124 – guanylate cyclase-activating proteins MeSH D12.644.360.381.500.249 – hippocalcin MeSH D12.644.360.381.500.374 – Kv channel-interacting proteins MeSH D12.644.360.381.500.500 – neurocalcin MeSH D12.644.360.381.500.750 – recoverin MeSH D12.644.360.400 – map kinase kinase kinases MeSH D12.644.360.400.100 – map kinase kinase kinase 1 MeSH D12.644.360.400.200 – map kinase kinase kinase 2 MeSH D12.644.360.400.300 – map kinase kinase kinase 3 MeSH D12.644.360.400.400 – map kinase kinase kinase 4 MeSH D12.644.360.400.500 – map kinase kinase kinase 5 MeSH D12.644.360.400.800 – proto-oncogene proteins c-mos MeSH D12.644.360.400.842 – raf kinases MeSH D12.644.360.400.842.249 – oncogene proteins v-raf MeSH D12.644.360.400.842.374 – proto-oncogene proteins b-raf MeSH D12.644.360.400.842.500 – proto-oncogene proteins c-raf MeSH D12.644.360.440 – mitogen-activated protein kinase kinases MeSH D12.644.360.440.100 – map kinase kinase 1 MeSH D12.644.360.440.200 – map kinase kinase 2 MeSH D12.644.360.440.300 – map kinase kinase 3 MeSH D12.644.360.440.400 – map kinase kinase 4 MeSH D12.644.360.440.500 – map kinase kinase 5 MeSH D12.644.360.440.600 – map kinase kinase 6 MeSH D12.644.360.440.700 – map kinase kinase 7 MeSH D12.644.360.450 – mitogen-activated protein kinases MeSH D12.644.360.450.169 – extracellular signal-regulated map kinases MeSH D12.644.360.450.169.500 – mitogen-activated protein kinase 1 MeSH D12.644.360.450.169.750 – mitogen-activated protein kinase 3 MeSH D12.644.360.450.169.875 – mitogen-activated protein kinase 6 MeSH D12.644.360.450.169.937 – mitogen-activated protein kinase 7 MeSH D12.644.360.450.340 – jnk mitogen-activated protein kinases MeSH D12.644.360.450.340.500 – mitogen-activated protein kinase 8 MeSH D12.644.360.450.340.750 – mitogen-activated protein kinase 9 MeSH D12.644.360.450.340.800 – mitogen-activated protein kinase 10 MeSH D12.644.360.450.835 – p38 mitogen-activated protein kinases MeSH D12.644.360.450.835.200 – mitogen-activated protein kinase 11 MeSH D12.644.360.450.835.400 – mitogen-activated protein kinase 12 MeSH D12.644.360.450.835.600 – mitogen-activated protein kinase 13 MeSH D12.644.360.450.835.800 – mitogen-activated protein kinase 14 MeSH D12.644.360.525 – monomeric gtp-binding proteins MeSH D12.644.360.525.100 – adp-ribosylation factors MeSH D12.644.360.525.100.100 – ADP-ribosylation factor 1 MeSH D12.644.360.525.400 – rab gtp-binding proteins MeSH D12.644.360.525.400.025 – rab1 gtp-binding proteins MeSH D12.644.360.525.400.050 – rab2 gtp-binding protein MeSH D12.644.360.525.400.100 – rab3 gtp-binding proteins MeSH D12.644.360.525.400.100.100 – rab3a gtp-binding protein MeSH D12.644.360.525.400.150 – rab4 gtp-binding proteins MeSH D12.644.360.525.400.200 – rab5 gtp-binding proteins MeSH D12.644.360.525.450 – ral gtp-binding proteins MeSH D12.644.360.525.462 – ran gtp-binding protein MeSH D12.644.360.525.475 – rap gtp-binding proteins MeSH D12.644.360.525.475.100 – rap1 gtp-binding proteins MeSH D12.644.360.525.500 – ras proteins MeSH D12.644.360.525.500.300 – oncogene protein p21(ras) MeSH D12.644.360.525.500.600 – proto-oncogene proteins p21(ras) MeSH D12.644.360.525.700 – rho gtp-binding proteins MeSH D12.644.360.525.700.050 – cdc42 gtp-binding protein MeSH D12.644.360.525.700.050.500 – cdc42 gtp-binding protein, saccharomyces cerevisiae MeSH D12.644.360.525.700.100 – rac gtp-binding proteins MeSH D12.644.360.525.700.100.100 – rac1 gtp-binding protein MeSH D12.644.360.525.700.200 – rhoa gtp-binding protein MeSH D12.644.360.525.700.300 – rhob gtp-binding protein MeSH D12.644.360.543 – olfactory marker protein MeSH D12.644.360.562 – phosphatidylethanolamine binding protein MeSH D12.644.360.581 – phospholipase c gamma MeSH D12.644.360.600 – ribosomal protein s6 kinases MeSH D12.644.360.600.249 – ribosomal protein s6 kinases, 70-kda MeSH D12.644.360.600.500 – ribosomal protein s6 kinases, 90-kda
Sources: en.wikipedia.org
Nalin Chandra Wickramasinghe (born 20 January 1939) is a Sri Lankan-born British mathematician and astronomer. His research interests include the interstellar medium, infrared astronomy, light scattering theory, applications of solid-state physics to astronomy, the early Solar System, comets, astrochemistry, the origin of life and astrobiology. A student and collaborator of Fred Hoyle, the pair worked jointly for over 40 years as the most famous proponents of a non-mainstream version of panspermia, the proposal that life was seeded (or continues to be seeded) on Earth through space-based processes. In 1974 they proposed that some dust in interstellar space matched the spectral characteristics of freeze-dried bacteria, which was largely ignored at its publishing while the ubiquity of polycyclic aromatic hydrocarbons explains the apparent match. Wickramasinghe has advanced numerous fringe claims, including the argument that various outbreaks of illnesses on Earth are of extraterrestrial origins, including the 1918 flu pandemic and certain outbreaks of polio and mad cow disease. For the 1918 flu pandemic they proposed that cometary dust brought the virus to Earth simultaneously at multiple locations—a view dismissed by experts on this pandemic. Claims connecting terrestrial disease and extraterrestrial pathogens have been rejected by the scientific community. Wickramasinghe has written more than 40 books about astrophysics and related topics; he has made appearances on radio, television and film, and he writes online blogs and articles.
== After WWII == In 1968, Victor Saxl died and Eva moved to Santiago, Chile, to live with her brother, her only living relative. There she would remain vigilant as an advocate for people with Type 1 diabetes. Eva Saxl died in 2002 in Santiago. The Saxls' story was dramatized by the 1956–1958 CBS television show Telephone Time in an episode titled "Time Bomb".
== See also == Argo Tea, Chicago based chain of tea cafés Bigelow Tea Company, founded in 1945 in Connecticut with a tea blended with orange and spices, family owned Celestial Seasonings, a pioneering American herbal tea company founded in Colorado, 1969 English breakfast tea, named by an English-American tea merchant in 1843 in New York City The Great Atlantic & Pacific Tea Company, began in 1859 as a tea and coffee dealer in New York; also known as the giant supermarket chain "A&P" List of tea companies#United States Luzianne, a Louisiana-based tea company that introduced an iced tea blend in 1932 Lynchburg lemonade, a cocktail and long drink Salada tea, a tea company founded in Montreal, that built a headquarters in Boston in 1917 Snapple, an American brand of tea and juice drinks which is owned by Dr Pepper Snapple Group and based in Plano, Texas Tea production in the United States Teahouse
Sources: en.wikipedia.org
During the COVID-19 pandemic, Pritzker took several measures to mitigate the pandemic in Illinois. On March 13, 2020, Pritzker declared that public and private schools in Illinois would be closed from March 17 through March 31. On March 15, he announced that all bars and restaurants must close until March 30. Restaurant businesses with delivery and takeout options would still be able to serve. On March 16, 2020, Pritzker issued an executive order limiting permitted crowd sizes to 50 people. Despite pressure from Chicago election officials, he refused to postpone the state's March 17 primary elections, since it was not something that he had the authority to do. On March 20, 2020, Pritzker issued a stay-at-home order to take effect the next day. Under this order, all non-essential businesses were required to close while essential businesses such as grocery stores, gas stations, hospitals, pharmacies remained open. The order originally ended on April 8. The state government coordinated a public health response. The State of Illinois worked with the U.S. Department of Health and Human Services, Wal-Mart, and Walgreens to provide testing sites in Illinois's hardest-hit communities. By June, amid unrest by some municipalities unhappy with Pritzker's lockdown orders, Mayor Keith Pekau of Orland Park, a suburb southwest of Chicago, and a local restaurateur sued Pritzker in federal court, alleging that the lockdown orders violated state law and the state constitution. U.S. District Judge Andrea Wood ruled against the plaintiffs, allowing the lockdown orders to stay in place.
A Mesmerian Experiment (French: Le Baquet de Mesmer) is a 1905 French silent trick film by Georges Méliès. It was sold by Méliès's Star Film Company and is numbered 693–695 in its catalogues. Méliès appears in the film Doctor Mesmer. The film has few illusions, and is mainly a vehicle for its troupe of dancers, identified in Méliès's American film catalogue as the "Snow-drops" of London's Alhambra Theatre of Variety. The film's technical effects were carried out with pyrotechnics and substitution splices.
=== New Zealand === Although there are no regulatory standards for the practice of TCM in New Zealand, in the year 1990, acupuncture was included in the Governmental Accident Compensation Corporation (ACC) Act. This inclusion granted qualified and professionally registered acupuncturists to provide subsidised care and treatment to citizens, residents, and temporary visitors for work or sports related injuries that occurred within and upon the land of New Zealand. The two bodies for the regulation of acupuncture and attainment of ACC treatment provider status in New Zealand are Acupuncture NZ and The New Zealand Acupuncture Standards Authority.
In November 1971, Douglas-Home renewed contacts with Salisbury and announced a proposed agreement that would be satisfactory to both sides – it recognised Rhodesia's 1969 constitution as the legal frame of government, while agreeing that gradual legislative representation was an acceptable formula for unhindered advance to majority rule. Nevertheless, the new settlement, if approved, would also implement an immediate improvement in black political status, offer a means to terminate racial discrimination, and provide a solid guarantee against retrogressive constitutional amendments. Implementation of the proposed settlement hinged on popular acceptance, but the Rhodesian government consistently refused to submit it to a universal referendum. A twenty four-member commission headed by an eminent jurist, Lord Pearce, was therefore tasked with ascertaining public opinion on the subject. In 1972, the commission began interviewing interest groups and sampling opinions – although concern was expressed over the widespread apathy encountered. According to the commission, whites were in favour of the settlement, and Rhodesians of Coloured or Asian ancestry generally pleased, while the black response to the settlement's terms was resoundingly negative. As many as thirty black Rhodesian chiefs and politicians voiced their opposition, prompting Britain to withdraw from the proposals on the grounds of the commission's report.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.
Albumin binding keeps a large fraction of the compound in a slowly released reservoir within the bloodstream. Plasma levels decline gradually rather than falling sharply after each administration. That profile supports dosing intervals measured in days instead of hours.
The active peptide sequence is the same in both formats. The oral version adds an absorption enhancer that is not present in the injected solution. Differences in excipients and formulation affect uptake rather than the identity of the active molecule.
Purity is commonly expressed as the percentage of the main peak relative to all integrated peaks in a reversed-phase chromatogram. Related substances and counter-ions are reported separately. Values obtained with different detectors are not always directly comparable.